Artificial axons as a biomimetic 3D myelination platform for the discovery and validation of promyelinating compounds.

ABSTRACT: Multiple sclerosis (MS), a chronic neurodegenerative disease driven by damage to the protective myelin sheath, is currently incurable. Today, all clinically available treatments modulate the immune-mediated symptoms of the disease but they fail to stop neurodegeneration in many patients. Remyelination, the regenerative process of myelin repair by oligodendrocytes, which is considered a necessary step to protect demyelinated axons and stop neuronal death, is impaired in MS patients. One of the major obstacles to finding effective remyelinating drugs is the lack of biomimetic drug screening platforms that enable quantification of compounds' potential to stimulate 3D myelination in the physiologically relevant axon-like environment. To address this need, we built a unique myelination drug dis

SUBMITTER: Jagielska A 

PROVIDER: S-EPMC10636046 | biostudies-literature | 2023 Nov

REPOSITORIES: biostudies-literature